OncoSec Medical Incorporated

(ONCS) Trade

By |

Established in 2011, OncoSec Medical Incorporated is a San Diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. Through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients.

OncoSec’s investigational platform, ImmunoPulse®, is designed to enhance local delivery and uptake of DNA-based therapeutics directly into tumors. Clinical studies of ImmunoPulse® with DNA-based IL-12 demonstrated a local immune response, and subsequently, a systemic effect. We are currently conducting pre-clinical and clinical studies targeting various cancers in collaboration with several prominent academic medical centers and companies.

To date, study results have laid the groundwork for OncoSec’s expansion into new DNA-encoded therapeutic candidates and tumor indications. Data also indicates this platform shows clinical activity as a monotherapy and promise as a combination approach.

Investment Highlights

  • Advancing a lead portfolio of gene therapies for cancer
  • Platform focused on reversing tumor immune suppression
  • Phase II clinical programs focused on addressing unmet need of T-cell poor tumors
  • Clinical data demonstrates proof of concept of the technology
  • Rapid preclinical development platform
  • Experienced leadership team

Clinical Pipeline

Technology Overview

IMMUNOPULSE® IL-12

To date, OncoSec’s immunotherapy platform, ImmunoPulse®, focuses on the delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The treatment is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, which in turn, enables the immune system to target and attack tumors throughout the body.

OncoSec is currently investigating ImmunoPulse® IL-12 for treatment of metastatic melanoma and triple negative breast cancer. As the company continues to evaluate ImmunoPulse® IL-12 in these current indications, OncoSec is developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches.

How It Works

Additional Information


In the interest of full disclosure, we call the reader's attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.

OncoSec Medical Incorporated

Profile

Established in 2011, OncoSec Medical Incorporated is a San Diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. Through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients.

Contact Information

Website: www.oncosec.com
Main Phone: +1 855 662-6732
Address: 9810 Summers Ridge Road
Address 2: Suite 110
State: CA
City / Town: San Diego
Country: USA
Postal Code: 92121

Issuer Information

Exchange: NSC
CEO: Punit Dhillon
Employees: 53
Issuer Type: CS - Common Stock
Sector/Industry: Cyclical
NAICS: In-Vitro Diagnos
$ 1.18 $ -0.0177 (-1.48%)
Last Price 1.18 Change $ -0.0177 Change % -1.48 Tick N/A
Bid 1.18 Bid Size 1,200.00 Ask 1.20 Ask Size 10,400.00
Open 1.19 High 1.21 Low 1.16 Prev Close 1.20
Last Trade Volume 355,300 52 Wk Hi 2.08 52 Wk Low 0.88
Market Cap 25 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 21,168,194.00 EPS (TTM) -1.14 PE Ratio N/A Exchange NCM
  Last 3 Mo Last 12 Mo
Number of Insider Trades 2 19
Number of Buys 2 19
Number of Sells 0 0
Net Activity 6000 396520
Last 10 Buys Shares
Punit Dhillon 1,000
Sheela Mohan-Peterson 1,000
Sheela Mohan-Peterson 1,000
Avtar Dhillon 1,000
Punit Dhillon 1,000
Punit Dhillon 1,000
Punit Dhillon 1,000
Punit Dhillon 1,000
Punit Dhillon 1,000
Punit Dhillon 1,000
Last 10 Sell Shares
N/A 0
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 11 11 11 11
Low Target Price Estimate 5 5 5 5
Mean Target Price Estimate 7.5 7.5 7.5 7.5
Standard Deviation 2.65 2.65 2.65 2.65
Date of Most Recent Estimate 07/21/16 07/21/16 07/21/16 07/21/16
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 4 4 3 3
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1 1 1 1